NOTE:    The following Minutes are provided for informational purposes only.

If you would like to obtain an official copy of these Minutes, please contact the

State Board of Pharmacy at 614/466-4143 for instructions and fee.

Minutes Of The Meeting

Ohio State Board of Pharmacy

September 10 & 11, 2002

TUESDAY, SEPTEMBER 10, 2002

8:05 a.m.	ROLL CALL
	The State Board of Pharmacy convened in Room East-B, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:
	Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Gregory Braylock, R.Ph.; Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Member; and James E. Turner, R.Ph.
	Also present were William T. Winsley, Executive Director; Timothy Benedict, Assistant Executive Director; William McMillen, Licensing Administrator; Mark Keeley, Legislative Affairs Administrator; David Rowland, Legal Affairs Administrator; Robert Cole, Compliance Supervisor; and Sally Ann Steuk, Assistant Attorney General.
8:08 a.m.	Mr. Braylock moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code and for the purpose of conferring with an attorney for the Board regarding pending or imminent court action pursuant to Section 121.22(G)(3) of the Revised Code. The motion was seconded by Mr. Turner and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.
10:50 a.m.	The Executive Session ended and the meeting was opened to the public.
R-2003-031	Ms. Eastman moved that, pursuant to Section 3719.121 of the Revised Code, the Board summarily suspend the license to practice pharmacy belonging to Maynard Dwight Turner, R.Ph. (03-2-09730) due to the fact that a continuation of his professional practice presents a danger of immediate and serious harm to others. The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).
R-2003-032	Mr. Kost then moved that the Board accept the settlement offer as revised by the Board received in the matter of Jack MacCartney, R.Ph. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).
	Mr. Rowland announced that the settlement agreements in the following matters had been signed by all parties and were effective as of the date of the signature of the Board President:

R-2003-033	SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY VOLUNTARY SURRENDER WITH DISCIPLINARY ACTION PENDING (Docket No. D-011206-023) In The Matter Of: Alvin Dorfman, R.Ph. 7718 Stonehenge Drive Cincinnati, Ohio (R.Ph. No. 03-3-07230)
	This Settlement Agreement is entered into by and between Alvin Dorfman and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code.
	Alvin Dorfman enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel and the right to a formal adjudication hearing on the issues contained herein.
	Alvin Dorfman is knowingly and voluntarily acknowledging that, in order to settle the disciplinary charges that have been filed by the Board against him and in order to obviate the need to conduct an administrative hearing to consider possible disciplinary sanctions against Alvin Dorfman’s license to practice pharmacy in the State of Ohio, this Agreement is entered into on the basis of the following stipulations, admissions, and understandings:

(A)	The Ohio State Board of Pharmacy is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card, or impose a monetary penalty on the license holder for violation of any of the enumerated grounds.
(B)	Alvin Dorfman neither admits nor denies the allegations stated in the Summary Suspension and Notice of Opportunity for Hearing letter dated December 6, 2001; however, the Board has evidence sufficient to sustain the allegations and hereby adjudicates the same:

(1)

That on or about October 15, 2001 in Montgomery County, State of Ohio, you did knowingly make a false statement for a prescription, order, report, or record required by Chapter 3719 or 4729 of the Ohio Revised Code. Further, you were found Guilty of this violation of O.R.C. 2925.23(A) by the Honorable Barbara P. Gorman of the Montgomery County Common Pleas Court on July 10, 2002.

Wherefore, in consideration of the foregoing and mutual promises hereinafter set forth, and in lieu of a formal hearing at this time, Alvin Dorfman knowingly and voluntarily surrenders PERMANENTLY to the State Board of Pharmacy his license and registration to practice pharmacy, with disciplinary action pending.

Alvin Dorfman acknowledges that he has had an opportunity to ask questions concerning the terms of this agreement and that all questions asked have been answered in a satisfactory manner.

Alvin Dorfman waives any and all claims or causes of action he may have against the State of Ohio or the Board, and members, officers, employees, and/or agents of either, arising out of matters which are the subject of this Agreement. Alvin Dorfman waives any rights of appeal pursuant to Chapter 119. of the Ohio Revised Code.

This Settlement Agreement shall be considered a public record, as that term is used in Section 149.43 of the Ohio Revised Code, and shall become effective upon the date of the Board President’s signature below.

/s/          Alvin Dorfman	/d/      07-10-02
Alvin Dorfman, Respondent	Date of Signature
/s/          M Sorg	/d/      7/10/02
Matthew C. Sorg, Attorney for Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      9-10-02
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      9-10-02
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-034	SETTLEMENT AGREEMENT WITH THE STATE BOARD OF PHARMACY (Docket No. D-020618-063) In The Matter Of: RICHARD A. RIDZON, R.PH. 5251 Steubenville Road SE Amsterdam, Ohio 43903 (R.Ph. No. 03-1-20844)
	This Settlement Agreement is entered into by and between Richard A. Ridzon and the Ohio State Board of Pharmacy, a state agency charged with enforcing the Pharmacy Practice Act and Dangerous Drug Distribution Act, Chapter 4729. of the Ohio Revised Code.
	Richard A. Ridzon voluntarily enters into this Agreement being fully informed of his rights afforded under Chapter 119. of the Ohio Revised Code, including the right to representation by counsel, the right to a formal adjudication hearing on the issues contained herein, and the right to appeal. Richard A. Ridzon acknowledges that by entering into this agreement he has waived his rights under Chapter 119. of the Revised Code.
	Whereas, the Board is empowered by Section 4729.16 of the Ohio Revised Code to suspend, revoke, place on probation, refuse to grant or renew an identification card or enforce a monetary penalty on the license holder for violation of any of the enumerated grounds therein. Whereas, Richard A. Ridzon is licensed to practice pharmacy in the State of Ohio.
	Whereas, on or about June 18, 2002, pursuant to Chapter 119. of the Ohio Revised Code, Richard A. Ridzon was notified of the allegations or charges against him, his right to a hearing, his rights in such hearing, and his right to submit contentions in writing. Further, a hearing was scheduled by the Board. The Notice of Opportunity for Hearing contains the following allegations or charges:

(1)

Records of the Board of Pharmacy indicate that you were originally licensed in the State of Ohio on November 2, 1994 pursuant to examination, and are currently licensed to practice pharmacy in the State of Ohio.

(2)

You did, on or about November 30, 2001, fail to perform prospective drug utilization review, to wit: when dispensing medications to a patient pursuant to prescription number 226292, you failed to review the original prescription and/or refill information for over-utilization, incorrect drug dosage and duration of drug treatment, and misuse. The medication, chloral hydrate 500mg/5ml, was prescribed for a four-year-old child, with the dose being 15ml, to be taken 30 minutes prior to dental procedure, with possible repeat one time. When the child was given the medication as labeled 30ml, he needed hospitalized. Such conduct is in violation of Rule 4729-5-20 of the Ohio Administrative Code, and if proven constitutes being guilty of unprofessional conduct in the practice of pharmacy and/or guilty of violating a rule of the Board within the meaning of Section 4729.16 of the Ohio Revised Code

Wherefore, the parties, in consideration of the mutual covenants and promises contained herein, and in lieu of any further formal proceedings at this time, and intending to be bound by said covenants, agree as follows:

(1)	Richard A. Ridzon agrees to the imposition of a monetary Three Hundred Dollars ($300.00) due and owing within 30 days of the effective date of this Agreement. The monetary penalty should be made payable to the “Treasurer, State of Ohio” and mailed with the enclosed form to the State Board of Pharmacy, 77 S. High Street, 17th Floor, Columbus, Ohio 43266-0320.
(2)	In addition to any and all other Continuing Education requirements, Richard A. Ridzon agrees to attend 4.0 hours of continuing education within two months of the effective date of this agreement for quality assurance.
(3)	Richard A. Ridzon agrees that that 2.0 hours of the 4.0 hours of continuing education will be concentrated on pediatric dosing.
(4)	Richard A. Ridzon acknowledges that he is not a “prevailing eligible party” for purposes of Revised Code Sections 119.092 and 2335.39. Further Richard A. Ridzon waives any rights he may have under Revised Code Sections 119.09 and 2335.39.
(5)	Richard A. Ridzon, with intention of binding himself and his successors in interest and assigns, hereby releases, and holds harmless from liability and forever discharges the State of Ohio, the Board, the Ohio Attorney General, and any and all of their present and former members, officers, attorneys, agents and employees, personally and in their official capacities, from any and all claims, demands, causes of actions, judgments, or executions that Richard A. Ridzon ever had, or now has or may have, known or unknown, or that anyone claiming through or under him may have or claims to have, created by or arising out of the allegations or charges filed by the Board against Richard A. Ridzon, set forth in the Notice of Opportunity for Hearing.
(7)	Richard A. Ridzon acknowledges that he has had an opportunity to ask questions concerning the terms of this Agreement and that all questions asked have been answered in a satisfactory manner.
(8)	This Agreement embodies the entire agreement between and of the parties. There are no express or implied promises, guarantees, terms, covenants, conditions, or obligations other than those contained herein; and this Agreement supersedes all previous communications, representations or agreements, either verbal or written, between the parties.
(9)	The parties hereto acknowledge that this Agreement shall be considered a public record as that term is used in Section 149.43 of the Ohio Revised Code and shall become effective upon the date of the Board President’s signature below.

/s/          Richard A. Ridzon	/d/      8/22/02
Richard A. Ridzon, Respondent	Date of Signature
/s/          Diane C. Adelman	/d/      9/10/02
Diane C. Adelman, President, Ohio State Board of Pharmacy	Date of Signature
/s/          Sally Ann Steuk	/d/      9-10-02
Sally Ann Steuk, Ohio Assistant Attorney General	Date of Signature

R-2003-035	Mr. Rowland also announced that ConvaMed Pharmaceutical, Inc. (02-1108800) has discontinued business and has filed the appropriate forms with the office. Due to this action, it was the consensus of the Board that the Notice of Opportunity For A Hearing (D-010615-075) that was issued to ConvaMed Pharmaceutical, Inc. on June 15, 2001 be dismissed.
R-2003-036	Mr. Turner then moved that the Board deny the request from Patrica Ann Flack, R.Ph. for a change to her Board Order. The motion was seconded by Mr. Braylock and approved by the Board (Aye-8/Nay-0).
11:10 a.m.	The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Dana F. Casper, R.Ph., Waynesville.
12:39 p.m.	The hearing ended and the record was closed. Mr. Giacalone moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mrs. Gregg and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.
12:48 p.m.	The Executive Session ended and the meeting was opened to the public.
R-2003-037	Mr. Giacalone moved that the Board adopt the following Order in the matter of Dana F. Casper, R.Ph.:

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020502-054)

In The Matter Of:

DANA FRANCES CASPER, R.Ph.

8495 State Route 48

Waynesville, Ohio 45068

(D.O.B. 06/09/1971)

INTRODUCTION

THE MATTER OF DANA FRANCES CASPER CAME FOR HEARING ON SEPTEMBER 10, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

DANA FRANCES CASPER WAS REPRESENTED BY ERIC J. PLINKE AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

SUMMARY OF EVIDENCE

State’s Witnesses

None

Respondent's Witnesses

1. Dana Frances Casper, R.Ph., Respondent

2. Wayne C. Miller, R.Ph.

State's Exhibits

1. Reinstatement Hearing Request letter from Dana F. Casper [05-03-02]

1A-1C. Procedurals

2. Copy of State Board of Pharmacy Order in re Dana Frances Casper, R.Ph. [09-13-01]

3. NABP Official Application For Transfer Of Pharmaceutic Licensure issued March 27, 2001 to Dana Frances Casper [04-07-01]

4. Alcohol Influence Report, Town and Country (Missouri) Police Department [11-13-99]

5. Completion Certificate, Missouri Substance Abuse Traffic Offenders' Program

6. Letter from Ben Capshaw, Esq. [06-21-01]

7. O'Fallon (Missouri) Police Department Alcohol Influence Report; Offense/Incident Report; Ticket 001793062, Driving While Intoxicated; Ticket 001793065, Fail to Yield to Emergency Vehicle; Ticket 001793084, No Proof of Insurance; Ticket 001793063, Following Too Closely [03-21-01]

8. Copy of handwritten memo of dispositions of tickets for Dana Casper

Respondent's Exhibits

A. State Board of Pharmacy Order in re Dana Frances Casper, R.Ph. [09-13-01]

B. Letter and Psychological Evaluation results from Jack C. Lunderman, Jr., M.D. [10-23-01]; Psychiatric Treatment Plan Compliance Report from Jack C. Lunderman, Jr., M.D. [09-04-02]

C. PRO Pharmacist’s Recovery Contract for Dana Casper [09-18-01]; Letters from Wayne C. Miller [11-13-01, 12-26-01, 01-06-02, 07-10-02]; Letter from Michael D. Quigley, R.Ph. [08-31-02]

D. Drug Screen Reports [10-16-01 to 08-23-02]

E. Support Group Attendance Records [07-31-01 to 09-09-02]

F. Psychiatric Treatment Plan Compliance Report from Bill Tayon, M.A., LPC [05-16-02]

G. Ten Letters of Support [01-09-02 to 08-26-02]

FINDING OF FACT

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds that Dana Frances Casper has complied with the terms set forth in the Order of the State Board of Pharmacy, Docket No. D-010727-006, effective September 13, 2001.

DECISION OF THE BOARD

On the basis of the Finding of Fact set forth above, and after consideration of the record as a whole, the State Board of Pharmacy hereby approves the issuance of a pharmacist identification card to Dana Frances Casper to practice pharmacy in Ohio and, therefore, will accept an Official application for reciprocity submitted by Dana Frances Casper.

Further, Dana Frances Casper will be placed on probation for five years from the effective date of this Order, with the following conditions:

(A) Dana Frances Casper must continue to abide by the terms of her Pharmacists Rehabilitation Organization Pharmacist's Recovery Contract signed September 18, 2001, and any violation must be reported to the Board immediately.

(B) Dana Frances Casper must submit quarterly progress reports to the Board (due January 10, April 10, July 10, and October 10 of each year of probation) that include:

(1) The written report and documentation provided by the treatment program pursuant to the contract, and

(2) A written description of Ms. Casper's progress towards recovery and what she has been doing during the previous three months.

(C) Other terms of probation are as follows:

(1) The State Board of Pharmacy hereby declares that Dana Frances Casper 's pharmacist identification card is not in good standing and thereby denies the privilege of being a preceptor and training pharmacy interns pursuant to paragraph (D)(1) of Rule 4729-3-01 of the Ohio Administrative Code.

(2) Dana Frances Casper may not serve as a responsible pharmacist.

(3) Dana Frances Casper may not destroy, assist in, or witness the destruction of controlled substances.

(4) Dana Frances Casper must not violate the drug laws of Ohio, any other state, or the federal government.

(5) Dana Frances Casper must abide by the rules of the State Board of Pharmacy.

(6) Dana Frances Casper must comply with the terms of this Order.

(D) Any violation of probation may result in a Board hearing to consider alternative or additional sanctions under Section 4729.16 of the Ohio Revised Code.

Dana Frances Casper is hereby advised that the Board may at any time revoke probation for cause, modify the conditions of probation, and reduce or extend the period of probation. At any time during this period of probation, the Board may revoke probation for a violation occurring during the probation period.

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

	The motion was seconded by Mrs. Gregg and approved by the Board (Aye-8/Nay-0).
12:50 p.m.	The meeting was recessed to allow the Board members to attend the reciprocity session.
1:00 p.m.	The Board reconvened in Room South-A, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio, for the purpose of meeting with the candidates for licensure by reciprocity with the following members present:
	Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Gregory Braylock, R.Ph.; Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Member; and James E. Turner, R.Ph.
R-2003-038	Following presentations by Board members and self-introductions by the candidates for licensure by reciprocity, Mr. Kost moved that the Board approve the following candidates for licensure. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

ALYCIA NICOLE BILLS	03-3-25490	TEXAS
CYNTHIA S. CHANG	03-3-25485	NORTH CAROLINA
EDDIE CHUNG-YOU CHEN	03-3-25483	TEXAS
MICHAEL FIEDLER CHICELLA	03-3-25475	NORTH CAROLINA
WILLIAM LEE HANSEN, JR.	03-3-25505	MICHIGAN
RODNEY M. JORSTAD	03-3-25502	OKLAHOMA
JAMES DAVID KAUCHAK, JR.	03-3-25479	NORTH CAROLINA
ZO LYNN LIVINGSTON	03-3-25476	TEXAS
ANNE LOWE	03-3-25444	UTAH
KATE EILEEN MCELWAIN	03-3-25500	NEW YORK
RANDY RAY MOORE	03-3-25473	MISSISSIPPI
LILIANA PACHECO	03-3-25148	PUERTO RICO
LANCE PIECORO	03-3-25498	KENTUCKY
RAJI NATARAJ REVAN	03-3-25477	MICHIGAN
JILL CHRISTINE TWEHUES	03-3-25488	MICHIGAN
RUTH MARY WETZEL	03-3-25506	INDIANA
WILLIAM JOHN WINTER	03-3-25497	MICHIGAN

1:15 p.m.	The Board meeting was recessed for lunch.
2:28 p.m.	The Board reconvened in Room East-B, 31st Floor, to continue the Board meeting . The Board was joined by representatives of Medtuity, an electronic prescribing system, for a presentation of their system.
2:54 p.m.	The meeting with the Medtuity representatives ended and the Board meeting continued with a discussion of agenda items.
	Mr. Braylock reported that there had been no meeting of the Nursing Board’s Committee on Prescriptive Governance.
	There was no report on the Medical Board’s Prescribing Committee.
	Mr. Benedict presented the Probation Report. There were only two exceptions, both of which had previously been dealt with.
R-2003-039	Mr. Keeley presented a revised set of proposed rule changes and additions on behalf of the Ad Hoc Committee on Rule Review, continuing the discussion from the August meeting. The Board members discussed the rules and suggested some additional changes. Mr. Braylock moved that the following rules, as amended, be approved for filing. The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

4729-3-01 Definitions.

As used in Chapter 4729-3 of the Administrative Code:

(A)	"Pharmacy internship" means the supervised practical experience required for licensure as a registered pharmacist. The purpose of the pharmacy internship program is to provide those individuals, who intend to become registered pharmacists, with the knowledge and practical experience necessary for functioning competently and effectively upon licensure.
(B)	"Supervised practical experience" is the experience obtained at an internship site and which is conducted in accordance with the "National Association of Boards of Pharmacy - American Association of Colleges of Pharmacy" publication "The Internship Experience," or a similar outline and/or manual approved by the board of pharmacy.
(C)	"Internship site" means a pharmacy licensed as a terminal distributor of dangerous drugs pursuant to Chapter 4729. of the Revised Code, except as provided in paragraph (C) or (D) of rule 4729-3-05 of the Administrative Code, and whose license is in good standing.
(D)	"Preceptor" is the individual responsible for seeing that the intern is properly supervised and exposed to all aspects of the internship program defined as the supervised practical experience.

(1)	A "preceptor" is a pharmacist who holds a current identification card which is in good standing; or, is a person who is of good moral character and is qualified to direct the approved experience in the area approved by the director of internship pursuant to paragraph (D) of rule 4729-3-05 of the Administrative Code.
(2)	A person may serve as the preceptor for more than one intern. The number of interns engaged in the practice of pharmacy at any time is limited to not more than two for each pharmacist on duty.
(3)	A preceptor must report to the board on the progress and aptitude of an intern when requested by the director of internship.

(E)	"Director of internship" has the same meaning as provided in section 4729.11 of the Revised Code.
(F)	"In good standing" means that the licensee or registrant has not been denied the privilege of supervising interns by the board.
(G)	"Statement of Preceptor" is the form which must be received by the board of pharmacy for each pharmacy intern within thirty days of beginning internship under a preceptor's supervision. A "Statement of Preceptor" form is not required to be submitted to the board when using an academic experience affidavit.

(1)	No credit will be given for practical experience obtained prior to thirty days of the date that the "Statement of Preceptor" form is received by the board office; except, that in the event of extraordinary circumstances and when due to no fault of the intern, the board may accept a retroactive date of filing for the "Statement of Preceptor."
(2)	The intern must file a "Statement of Preceptor" form whenever he/she changes internship sites and/or preceptors.

(H)	"Practical experience affidavit" is the form which must be used to submit practical experience for internship credit.

(1)	Practical experience must be itemized to the nearest half hour reported on the affidavit by shall be the total number of hours obtained each week during the reported time period rounded to the nearest hour. The hours reported must be able to be documented by payroll or other records which may be examined by the board of pharmacy upon reasonable notice.
(2)	Practical experience affidavits must be signed by the preceptor on file with the board of pharmacy. In the event of the unavailability of the preceptor's signature due to extraordinary circumstances and due to no fault of the intern, the board may accept an alternative method for verification of a practical experience affidavit.
(3)	Practical experience affidavits for a calendar year may be filed at any time, except that they must be received in the board office or postmarked no later than the first day of March of the following year.

(I)	"Academic experience affidavit" is the form that may be used to submit practical experience obtained from a structured program where academic credit is awarded.

(1)	The academic experience coordinator at a school of pharmacy is responsible for assuring that during the time of the experience each practice site and preceptor are currently licensed and are in good standing with the appropriate professional licensing board or have been previously approved by the board of pharmacy.
(2)	The preceptor at each practice site must sign the academic experience affidavit certifying the hours of practical experience obtained by the intern.
(3)	The academic experience coordinator at a school of pharmacy must submit a signed academic experience affidavit certifying that the intern obtained a passing grade and that the practice sites and the preceptors are currently licensed and in good standing with the appropriate professional licensing board or have been previously approved by the board of pharmacy.
(4)	The academic experience coordinator at a school of pharmacy is responsible for maintaining records of intern experience at each practice site.
(5)	Academic experience affidavits may be filed at any time, except that they must be received in the board office or postmarked no later than the first day of the July that immediately follows the successful completion of the academic course.

(I)(J)

"School of pharmacy" has the same meaning as a college of pharmacy or a department of pharmacy of a university, which has been recognized and approved by the state board of pharmacy.

4729-3-02 Registration as a pharmacy intern.

(A)	A certificate of registration as a pharmacy intern shall only be issued for the purpose of allowing those individuals who intend to become registered pharmacists the opportunity to obtain the practical experience required for examination and registration as a pharmacist.
(B)	If a person is actively working towards the requirements for licensure as a pharmacist and desires to work as a pharmacy intern in Ohio, he/she must:

(1)  (a)	Have successfully completed forty-eight semester or seventy-two quarter hours of college and have been accepted into be enrolled in a school of pharmacy; or
(2) (b)	Have obtained a first professional degree in pharmacy from a program which has been recognized and approved by the state board of pharmacy; or
(3) (c)	Have established educational equivalency by obtaining a Foreign Pharmacy Graduate Examination Commission (FPGEC) certificate, and have established proficiency in spoken English by successfully completing the Test of Spoken English (TSE) or its equivalent;.

(4)(2)

Apply to the state board of pharmacy for registration as a pharmacy intern.

4729-3-03 Application for registration as a pharmacy intern.

(A)	Every person desiring to register as a pharmacy intern shall submit the following to the state board of pharmacy:

(1)	A completed application form as provided by the board;
(2)	A three- by four-inch head and shoulders photograph taken within the previous six months;
(3)	Fee;
(4)	A An original transcript certifying that the applicant has in fact successfully completed a minimum of forty-eight semester or seventy-two quarter hours of college work; and
(5)	A certificate of acceptance enrollment into a school of pharmacy certifying that the person is enrolled in a school of pharmacy and is actively working towards the requirements for licensure as a pharmacist; or
(6)	All items listed in paragraphs (A)(1) to (A)(3) of this rule and:

(a)	certification Certification of having obtained a first professional degree in pharmacy from a program which has been recognized and approved by the state board of pharmacy; or
(b)	certification Certification of having established educational equivalency by obtaining a “Foreign Pharmacy Graduate Examination Commission (FPGEC)” certificate, and evidence of successful completion of the “Test of Spoken English (TSE)” or its equivalent.

(B)	The state board of pharmacy may register an applicant as a pharmacy intern as soon as the state board of pharmacy receives all the required items set forth in paragraphs (A)(1) to (A)(5) or paragraph (A)(6) of this rule.
(C)	The state board of pharmacy may, pursuant to rule 4729-5-04 of the Administrative Code, deny the issuance of a certificate of registration or an identification card to practice as a pharmacy intern.

4729-3-04 Pharmacy intern identification card renewal.

A pharmacy intern may renew his/her identification card each year provided he/she is actively working toward the requirements for licensure as a pharmacist and otherwise meets the requirements and rules of the state board of pharmacy. The state board of pharmacy may, pursuant to rule 4729-5-04 of the Administrative Code, deny the issuance of an identification card to practice pharmacy as an intern.

(A)	An intern shall be considered to be actively working towards licensure as a pharmacist if he/she has complied with all of the statutes and rules regarding internship since registration as a pharmacy intern, and:

(1)	He/she is enrolled in a school of pharmacy or is able to provide evidence that he/she has been accepted for enrollment in a school of pharmacy and is actively working towards the requirements for licensure as a pharmacist; or
(2)	He/she is a member of the armed forces and can provide evidence that he/she has been accepted for enrollment in a school of pharmacy upon his/her release from the armed forces; or
(3)	He/she is able to provide evidence of obtaining a first professional degree in pharmacy from a school of pharmacy; or
(4)	He/she is able to provide evidence of obtaining a “Foreign Pharmacy Graduate Examination Commission (FPGEC)” certificate, and can provide evidence of successful completion of the “Test of Spoken English (TSE)” or its equivalent.

(B)

An intern who has obtained a first professional degree in pharmacy from a school of pharmacy, or who has established equivalency by obtaining a “Foreign Pharmacy Graduate Examination Commission (FPGEC)” certificate, may renew his/her license only once. In the event of extraordinary circumstances and when due to no fault of the intern, the board may approve additional renewals.

4729-3-05 Internship credit.

(A)	No internship credit shall be granted by the board for practical experience obtained before registration as an intern or during a period when the intern's registration has lapsed.
(B)	Internship credit may be granted for practical experience obtained when the intern is registered and attending classes in the academic program of a school of pharmacy actively working towards the requirements for licensure as a pharmacist as defined in paragraph (A) of rule 4729-3-04 of the Administrative Code, other than the structured academic program as provided for in paragraph (C) of this rule.
(C)	Internship credit may be gained for practical experience obtained in a structured program for which academic credit is awarded (e.g., externship, clerkship). Such credit shall be limited to the number of hours for which the structured program has been approved by the state board of pharmacy. Internship credit shall be granted only when the intern obtains a passing grade for the course involved. A school of pharmacy which desires to conduct such structured programs eligible for approval shall make a written request on forms provided by the board The practical experience obtained may be submitted to the board on an academic experience affidavit.
(D)	Up to five hundred hours of internship credit may be obtained at a site other than a pharmacy licensed as a terminal distributor of dangerous drugs (e.g., manufacturing, research, consulting, drug information, and drug utilization review). To receive credit for such experience, a formal request must be submitted to the director of internship for approval prior to beginning the experience in these areas. The request shall include a detailed description of the contemplated internship with respect to time, place, duties, responsibilities, professional supervision, and the person supervising the experience. The request must be signed by both the intern and the person supervising the experience and returned with a completed statement of preceptor form.
(E)	Internship credit may be denied for the practical experience accumulated when an intern is found to be guilty of violation(s) pursuant to section 4729.16 of the Revised Code.
(F)	The pharmacy internship requirement for the licensure examination shall be deemed satisfactorily completed when the intern has filed affidavits certifying that he/she has obtained a total of one thousand five hundred hours of supervised practical experience and such affidavits have been accepted by the board of pharmacy.

4729-5-01 Definitions.

As used in Chapter 4729. of the Revised Code:

(A)	"Practice of pharmacy" is as defined in division (B) of section 4729.01 of the Revised Code.
(B)	The term "dispense" means the final association of a drug with a particular patient pursuant to the prescription, drug order, or other lawful order of a prescriber and the professional judgment of and the responsibility for: interpreting, preparing, compounding, labeling, and packaging a specific drug.
(C)	The term "compounding" has the same meaning as defined in division (C) of section 4729.01 of the Revised Code.
(D)	"Interpret prescriptions" means the professional judgment of a pharmacist when reviewing a prescription order of a prescriber for a patient.
(E)	"To participate in drug selection" means selecting and dispensing a drug product pursuant to sections 4729.38 and 4729.381 of the Revised Code.
(F)	"To participate with prescribers in reviews of drug utilization" means monitoring the appropriate use of drugs through communication with the prescriber(s) involved.
(G)	"Pharmacist" means an individual who holds a current pharmacist identification card pursuant to section 4729.08 or 4729.09 of the Revised Code; or, pursuant to section 4729.12 of the Revised Code.
(H)	"Original prescription" means the prescription issued by the prescriber in writing, an oral or electronically transmitted prescription recorded in writing by the pharmacist, or a prescription transmitted by use of a facsimile machine, or a prescription transmitted by a board-approved electronic prescription transmission system, each of which is pursuant to rule 4729-5-30 of the Administrative Code.
(I)	"Personal supervision" means a pharmacist shall be physically present in the pharmacy and provide personal review and approval of all professional pharmaceutical activities.
(J)	"Preprinted order" is defined as a patient-specific, definitive set of drug treatment directives to be administered to an individual patient who has been examined by a prescriber and for whom the prescriber has determined that the drug therapy is appropriate and safe when used pursuant to the conditions set forth in the preprinted order. Preprinted orders may be used only for inpatients in an institutional facility as defined in Chapter 4729-17 of the Administrative Code.
(K)	"Standing order" will mean the same as the term "protocol".
(L)	"Protocol" is defined as:

(1)

A definitive set of treatment guidelines that include definitive orders for drugs and their specified dosages which have been authorized by a prescriber as defined in rule 4729-5-15 of the Administrative Code and have been approved by the state board of pharmacy to be used by certified or licensed health care professionals when providing limited medical services to individuals in an emergency situation when the services of a prescriber are not immediately available; or

(2)

A definitive set of treatment guidelines that include definitive orders for drugs and their specified dosages which have been authorized by a prescriber as defined in rule 4729-5-15 of the Administrative Code and have been approved by the state board of pharmacy to be used by certified or licensed health care professionals when administering biologicals or vaccines to individuals for the purpose of preventing diseases.

	A protocol may be used only by licensed or certified individuals acting within the scope of their license or certification who have been adequately trained in the safe administration and use of the drugs and other procedures included in the protocol.
	Protocols submitted for approval by the state board of pharmacy may be reviewed with the medical and/or nursing board, as appropriate, prior to any approval by the state board of pharmacy.
(M)	"Prescriber" means any person authorized by the Revised Code to prescribe dangerous drugs as part of their professional practice.
(N)	"Positive identification" means a method of identifying an individual who prescribes, administers, or dispenses a dangerous drug. Such method must include a physical means of identification such as, but not limited to, the following:

(1)	A manual signature on a hard-copy record;
(2)	A magnetic card reader;
(3)	A bar code reader;
(4)	A thumbprint reader or other biometric method; or
(5)	A daily printout of every transaction that is verified and manually signed within twenty-four hours by the individual who prescribed, administered, or dispensed the dangerous drug. The printout must be maintained for three years and made available on request to those individuals authorized by law to review such records.

A magnetic card reader or a bar code reader system of identification must also include a private personal identifier, such as a password, for entry into a mechanical or automated system.

4729-5-15 Prescriber.

(A)

For purposes of division (Z) of section 3719.01 and division (I) of section 4729.01 of the Revised Code, the following persons, maintaining current licenses and in good standing, licensed pursuant to Chapters 4715., 4725., 4731., and 4741. of the Revised Code, are authorized by law to write prescriptions for drugs or dangerous drugs in the course of their professional practice:

(1)	Chapter 4715. of the Revised Code: dentist.
(2)	Chapter 4725. of the Revised Code: optometrist, if that person holds a current "therapeutic pharmaceutical agents certificate" as defined in division (H) of section 4725.01 of the Revised Code.
(3)	Chapter 4731. of the Revised Code: doctor of medicine, doctor of osteopathic medicine and surgery, and doctor of podiatry.
(4)	Chapter 4741. of the Revised Code: doctor of veterinary medicine.

(B)	Those persons pursuing an approved internship, residency, or fellowship program in this state are authorized to write prescriptions only when acting within their scope of employment in the hospital(s) or institution(s). Approved internship and residency programs are those accredited by the "Accreditation Council for Graduate Medical Education (ACGME)" or the "American Osteopathic Association (AOA)". Approved clinical fellowships are those at institutions which have a residency program in the same or a related clinical field which is accredited by the ACGME or the AOA.
(C)	A non-resident prescriber whose license is current and in good standing and who is authorized to issue prescriptions for drugs in the course of their professional practice in a state other than Ohio is authorized to write prescriptions in that state for drugs to be dispensed in the state of Ohio.
(D)	An advanced practice nurse approved pursuant to section 4723.56 of the Revised Code may, by written or oral prescription, prescribe those drugs which have been approved by the formulary committee for advanced practice nurses and that are included in the collaborative protocol established for that advanced practice nurse pursuant to section 4723.56 of the Revised Code.

4729-5-24 Prescription copy.

(A)	A pharmacist may transfer a copy of a prescription; a pharmacist may refill a copy of a prescription; such actions must be in accordance with the following:

(1)

Copies of prescriptions shall be transferred only between pharmacists except as provided in paragraph (G) of this rule; copies of prescriptions for controlled substances pursuant to sections 3719.41, 3719.43, and 3719.44 of the Revised Code shall be communicated directly between two pharmacists and shall be transferred only one time. However, pharmacies electronically sharing a real-time, on-line database may transfer a controlled substance prescription up to the maximum number of refills permitted by law and the prescriber's authorization pursuant to paragraph (A)(4) of this rule.

(2)

The copy transferred shall be an exact duplicate of the original prescription except that it shall also include:

(a)	Serial prescription number assigned to the prescription;
(b)	Name and address (and "D.E.A." number for controlled substance prescriptions) of the pharmacy transferring the copy;
(c)	Date of issuance of the prescription;
(d)	Date of original dispensing of the prescription;
(e)	Original number of refills;
(f)	Date of last refill;
(g)	Number of valid refills remaining; and
(h)	The full name of the transferring pharmacist.

(3)	Copies transferred for non-refillable prescriptions shall be marked on the face of the prescription or orally noted by the transferring pharmacist "For Information Purposes Only" and are not valid prescriptions for the dispensing of drugs.
(4)	The pharmacist transferring a copy of a prescription must:

(a)	Cancel the original prescription by writing the word "void" on the face of the prescription in such a way as to avoid destroying any of the original information contained on the prescription;
(b)	Record on the reverse side of the original written prescription:

(i)	Date of transfer;
(ii)	His/her signature; and
(iii)	When transferring an oral prescription, the name and address (and "D.E.A." number for controlled substance prescriptions) of, and name of the pharmacist at, the receiving pharmacy.

(c)

Except, if an automated data processing system is being used as an alternate system of recordkeeping for prescriptions pursuant to rules 4729-5-27 and 4729-5-28 of the Administrative Code, copies of prescriptions may be transferred by a pharmacist if the prescription record in the system is invalidated to prevent further dispensing at the original site. The prescription record in the system must contain the date of transfer, name of pharmacist making transfer, and the name and address of the pharmacy receiving the copy. Also, original written prescriptions for controlled substances must be canceled as required in paragraphs (A)(4)(a) and (A)(4)(b) of this rule.

(5)	The pharmacist receiving a copy of a prescription must:

(a)	Exercise reasonable diligence to determine validity of the copy;
(b)	Reduce an oral prescription to writing by recording all of the information transferred (must include all information required in paragraph (A)(2) of this rule) and write the word "transfer" on the face of the prescription;
(c)	Record date of transfer on the face of the prescription.

(B)	A prescription copy may be transferred between two pharmacies if the two pharmacies are accessing the same prescription records in a centralized database or pharmacy computers linked in any other manner. The computerized systems must satisfy all information requirements of paragraphs (A)(2) and (A)(4)(c) of this rule. This shall include invalidation of the prescription record in the system to prevent further dispensing at the original site and, if a controlled substance prescription, the canceling of the original written prescription as required in paragraphs (A)(4)(a) and (A)(4)(b) of this rule. A system must be in place that will allow only authorized access to these computerized prescription records by a pharmacist and indicate on the prescription record when and by whom such access was made.
(C)	A prescription copy may be transferred between two pharmacists by the use of a facsimile machine. This facsimile may be considered to be a copy of a prescription if all information requirements of paragraph (A) of this rule, including invalidation of the original prescription or computer records, are met. A system must be in place that will show on the facsimile positive identification of the transferring and receiving pharmacists which must become a part of the prescription record. Facsimile copies must be recorded in writing pursuant to section 4729.37 of the Revised Code, or stored in such a manner that will allow retention of the prescription record for three years from the date of the last transaction.
(D)	Information on a prescription is the property of the patient and is intended to authorize the dispensing of a specific amount of medication for use by the patient. Original copies of prescriptions shall be maintained by pharmacies for the purpose of documenting the dispensing of drugs to a particular patient.

(1)	In the event that the pharmacy is not able to provide the medication when needed by the patient pursuant to an authorized refill, the pharmacist shall, upon the request of the patient, transfer the prescription information to the pharmacy designated by the patient.
(2)	No pharmacy shall refuse to transfer information about a previously dispensed prescription to another pharmacy when requested by the patient. Prescription information shall be transferred in accordance with this rule as soon as possible in order to assure that the patient’s drug therapy is not interrupted.

(E)	Prescriptions entered into a computer system but not dispensed may be transferred to another pharmacy if all of the following conditions are met:

(1)	The complete prescription information has been entered into the computer system;
(2)	The information is displayed on the patient’s profile;
(3)	There is positive identification, either in the computer system or on the hard-copy prescription, of the pharmacist who is responsible for entering the prescription information into the system;
(4)	The original prescription is filed in accordance with rule 4729-5-09 of the Administrative Code;
(5)	All requirements of this rule are met for the transfer of the prescription.

(F)	Transfer of prescription information between two pharmacies which are accessing the same real-time, on-line database pursuant to the operation of a board-approved central filling operation shall not be considered a prescription copy and, therefore, is not subject to the requirements of this rule.
(G)	A licensed pharmacy intern may send or receive copies of prescriptions pursuant to the following:

(1)	The pharmacist on duty who is supervising the activity of the intern will determine if the intern is competent to send or receive a prescription copy.
(2)	The pharmacist on duty who is supervising the activity of the intern is responsible for the accuracy of a prescription copy that is sent or received by an intern.
(3)	The supervising pharmacist must be immediately available to answer questions or discuss the prescription copy that is sent or received by an intern.
(4)	The intern may not send or receive a prescription copy for a controlled substance.
(5)	The pharmacist or intern receiving a prescription copy from an intern must document the full names of the sending intern and his/her supervising pharmacist. The receiving intern shall immediately reduce the prescription copy to writing and shall review the prescription with the supervising pharmacist. Prior to dispensing, positive identification of the intern and the supervising pharmacist shall be made on the prescription to identify the responsibility for the receipt of the copy.
(6)	The pharmacist or intern sending a prescription copy to an intern must document the full names of the receiving intern and his/her supervising pharmacist. There must be documented positive identification of the sending intern and his/her supervising pharmacist who authorized the transfer of the prescription copy.
(7)	The approved intern and the supervising pharmacist must meet all the requirements of this rule.

4729-5-30 Manner of issuance of a prescription.

(A)

A prescription, to be valid, must be issued for a legitimate medical purpose by an individual prescriber acting in the usual course of his/her professional practice. The responsibility for the proper prescribing is upon the prescriber, but a corresponding responsibility rests with the pharmacist who dispenses the prescription. An order purporting to be a prescription issued not in the usual course of bona fide treatment of a patient is not a prescription and the person knowingly dispensing such a purported prescription, as well as the person issuing it, shall be subject to the penalties of law.

(B)

All prescriptions issued by a prescriber shall:

(1)	Be dated as of and on the day when issued.
(2)	Indicate Contain the manually printed, typewritten, or pre-printed full name and address of the prescriber.
(3)	Indicate a telephone number where the prescriber can be personally contacted during normal business hours.
(4)	Indicate the full name and address of the patient.
(4)(5)	Indicate the drug name and strength.
(5)(6)	Indicate the quantity to dispense.
(6)(7)	Indicate the appropriate directions for use.
(7)(8)	Specify the number of times or the period of time for which the prescription may be refilled. If no such authorization is given, the prescription may not be refilled except in accordance with section 4729.281 of the Revised Code. A prescription marked "Refill P.R.N." or some similar designation is not considered a valid refill authorization.
(8)(9)	Not authorize any refills for schedule II controlled substances.
(9)(10)	Authorize refills for schedules III and IV controlled substances only as permitted by section 3719.05 of the Revised Code.
(10)(11)	Not authorize a refill beyond one year from the date of issuance for schedule V controlled substances and for dangerous drugs that are not controlled substances.
(11)(12)	Identify the trade name or generic name of the drug(s) in a compounded prescription.
(12)(13)	Not be coded in such a manner that it cannot be dispensed by any pharmacy of the patient's choice.
(13)(14)	For prescriptions issued to a patient by a prescriber, be:

(a)	Manually signed on the day issued by the prescriber in the same manner as he/she would sign a check or legal document.
(b)	Issued in compliance with rule 4729-5-13 of the Administrative Code.

(14)(15)

Be issued in compliance with all applicable federal and state laws, rules, and regulations.

(C)	When forms are used that create multiple copies of a prescription issued to a patient by a prescriber, the original prescription that bears the actual signature of the prescriber must be issued to the patient for dispensing by a pharmacist.
(D)	A pharmacist may not dispense a dangerous drug for the first time beyond six months from the date of issuance of a prescription.
(E)	Oral transmission by the prescriber or the prescriber’s agent of original prescriptions and refills authorized by a prescriber, pursuant to the requirements of this rule, may be transmitted by telephone only to:

(1)	A pharmacist. The prescriber or prescriber’s agent must provide his/her full name. The pharmacist shall make a record of the prescriber's agent on the original prescription and, if used, on the alternate system of recordkeeping. The pharmacist is responsible for assuring the validity of the source of the oral prescription.
(2)	A recording device within the pharmacy if the pharmacist is unavailable. The prescriber or prescriber's agent must provide his/her full name. The pharmacist must remove the prescription from the recorder and reduce it to writing. The pharmacist is responsible for assuring the validity of the prescription removed from the recorder.
(3)	A licensed pharmacy intern if the pharmacist on duty who is supervising the activity of the intern determines that the intern is competent to receive telephone prescriptions.

(a)	The intern shall immediately reduce the prescription to writing and shall review the prescription with the supervising pharmacist. Prior to dispensing, positive identification of the intern and the supervising pharmacist shall be made on the prescription to identify the responsibility for the receipt of the oral order.
(b)	The supervising pharmacist on duty is responsible for the accuracy of the prescription.
(c)	The supervising pharmacist on duty must be immediately available to answer questions or discuss the prescription with the caller.

(F)	Original written prescriptions authorized and signed by a prescriber may be transmitted by the prescriber or the prescriber’s agent by facsimile machine to a pharmacy pursuant to the following:

(1)	The prescription must be issued in compliance with this rule.
(2)	The original prescription signed by the prescriber from which the facsimile is produced shall not be issued to the patient. The original prescription signed by the prescriber must remain with the patient’s records at the prescriber’s office or the institutional facility where it was issued.
(3)	Such a facsimile shall only be valid as a prescription if a system is in place that will allow the pharmacist to maintain the facsimile as a part of the prescription record including the positive identification of the prescriber and his/her agent as well as positive identification of the origin of the facsimile.
(4)	The pharmacist must record the prescription in writing pursuant to section 4729.37 of the Revised Code or store the facsimile copy in such a manner that will allow retention of the prescription record for three years from the date of the last transaction.
(5)	Prescriptions for schedule II controlled substances may not be transmitted by facsimile except:

(a)	Pursuant to rules 4729-17-09 and 4729-19-02 of the Administrative Code.
(b)	For a narcotic substance issued for a patient enrolled in a hospice. The original prescription must indicate that the patient is a hospice patient. The facsimile transmission must also meet the other requirements of this rule.

(6)	A facsimile of a prescription received by a pharmacy in any manner other than transmission directly from the prescriber or the prescriber’s agent shall not be considered a valid prescription, except as a copy of a prescription pursuant to rule 4729-5-24 of the Administrative Code.

(G)	A prescription may be transmitted by means of a board-approved electronic prescription transmission system, without further verification by the pharmacist of the prescriber’s identity, provided that:

(1)	The system shall require positive identification of the prescriber as defined in rule 4729-5-01 of the Administrative Code and the full name of any authorized agent of the prescriber who transmits the prescription.
(2)	The computer data must be retained for a period of three years at the prescriber's office.

(H)	A pharmacist who modifies a patient's drug therapy pursuant to a consult agreement and:

(1)	Is also responsible for the dispensing of the drug to the patient must include on the drug order the name of the physician who originally prescribed the drug, sign the pharmacist's full name, and be in compliance with this rule in the same manner as the prescriber.
(2)	Is not responsible for the dispensing of the drug to the patient may transmit the order to a pharmacy by acting as an agent of the physician. Such pharmacist must personally transmit the order verbally or by facsimile to another pharmacist and be in compliance with this rule.

4729-5-31 Criteria for licensure by examination.

(A)	Pursuant to section 4729.07 of the Revised Code:

(1)	The examination shall consist of the “North American Pharmacist Licensure Examination (NAPLEX)” and a jurisprudence examination compiled by the state board of pharmacy or the “National Association of Boards of Pharmacy (NABP).”

(2)  (a)	The minimum passing score for the NAPLEX is seventy-five. Any candidate failing to attain a score of seventy-five on the NAPLEX examination will be required to repeat the NAPLEX examination and remit the fee established by the state board of pharmacy for re-examination.
(b)	Pursuant to the procedures established by the NABP, a candidate may transfer his/her NAPLEX score to Ohio only after the candidate has met all of the requirements set by the board for examination and licensure in Ohio.

(3)

The minimum passing score for the jurisprudence examination is seventy-five. Any candidate who fails to receive a score of seventy-five on the jurisprudence examination will be required to repeat the jurisprudence examination and remit the fee established by the state board of pharmacy for re-examination.

(B)	Pursuant to section 4729.13 of the Revised Code:

(1)	The examination shall consist of the "North American Pharmacist Licensure Examination (NAPLEX)" and a jurisprudence examination compiled by the state board of pharmacy or the "National Association of Boards of Pharmacy (NABP)."
(2)	The minimum passing scores for renewal of the pharmacist's identification card is a seventy-five on each exam.

(a)	Any candidate for renewal of an identification card who fails to receive a score of seventy-five on the jurisprudence examination shall make application and remit the fee established by the state board of pharmacy for re-examination.
(b)	Any candidate for renewal of an identification card who fails to receive a score of seventy-five on the NAPLEX examination shall make application and remit the fee established by the state board of pharmacy for re-examination.

(C)	Pursuant to section 4729.08 of the Revised Code: Applicants for examination and registration as a pharmacist who are graduates of schools or colleges of pharmacy located outside the United States and who are using an approved examination to establish equivalency of their education shall:

(1)	Obtain a score no lower than seventy-five on the "Foreign Pharmacy Graduate Equivalency Examination (FPGEE)"; and
(2)	Show oral proficiency in English by successful completion of the "Test of Spoken English (TSE)" or its equivalent, pursuant to rule 4729-5-34 of the Administrative Code.

(D)	Any examination candidate who fails to take both of the required examinations within twelve months from the date the board receives the application materials shall submit a new application for the required examination or examinations and remit the fee established by the state board of pharmacy.
(E)	The record of the passing score for an examination candidate who takes both of the required examinations, but successfully only completes one examination will:

(1)	Be maintained if no more than twelve months has elapsed between attempts to successfully complete the remaining examination.
(2)	Not be maintained if more than twelve months has elapsed between attempts to successfully complete the remaining examination. It will then be necessary for the examination candidate to repeat both examinations for Ohio licensure.

(F)	Any candidate who has requested to transfer their NAPLEX score to Ohio must receive a passing score on the Ohio jurisprudence examination within twelve months from the date the board receives the initial application or the transfer of their NAPLEX score will be denied.

4729-9-08 Change in description of terminal or wholesale dangerous drug facility.

For the purpose of division (E) of section 4729.51 and division (D) of section 4729.52 of the Revised Code, any change in the ownership, business or trade name, or address of a terminal or wholesale distributor of dangerous drugs requires a new application, required fee, and license.

	Mr. Winsley distributed documentation received from NABP regarding the recent ACPE decisions about the accreditation status of the Lebanese American University and Canadian Pharmacy School graduates for the Board members to review. After a brief discussion, it was obvious that the Board will have to consider several issues relating to these decisions at a future meeting.
	Mr. Winsley then distributed an outline of the Fiscal Years 2004 and 2005 biennial budget as submitted for the Board members review and comment.
4:52 p.m.	Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code. The motion was seconded by Mr. Braylock and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.
4:57 p.m.	The Executive Session ended and the meeting was opened to the public.
	After discussion, Mrs. Gregg moved that the minutes of the August 5, 6, 7, 2002, meeting be approved as amended. The motion was seconded by Mr. Braylock and approved by the Board (Aye-8/Nay-0).
5:15 p.m.	The meeting was recessed until Wednesday, September 11, 2002.

WEDNESDAY, SEPTEMBER 11, 2002

10:30 a.m.	ROLL CALL
	The State Board of Pharmacy convened at the Villa Milano, 1630 Schrock Road, Columbus, Ohio with the following members present:
	Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Gregory Braylock, R.Ph.; Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Member; and James E. Turner, R.Ph.
	The Board met with members of the Ohio Pharmacists Association (OPA) Board of Directors and staff for a discussion of items of mutual interest. There were no items requiring official action by the Board.
11:44 a.m.	The meeting with the OPA Board of Directors ended.
11:45 a.m.	Mr. Braylock moved that the Board receive Per Diem as follows:

PER DIEM	09/10	09/11
Adelman	1	1
Braylock	1	1
Eastman	1	1
Giacalone	1	1
Gregg	1	1
Kost	1	1
Lipsyc	1	1
Teater	1	1
Turner	1	1

	The motion was seconded by Mrs. Gregg and approved by the Board (Aye-8/Nay-0).
11:46 a.m.	Mr. Lipsyc moved that the meeting be adjourned. The motion was seconded by Mr. Giacalone and approved (Aye-8/Nay-0).

THE BOARD APPROVED THESE MINUTES

OCTOBER 15, 2002